Apple Scores Another Win in Patent Dispute with Masimo Over Blood Oxygen Monitoring

• April 18, 2026

Apple has secured a significant, albeit not final, victory in its ongoing legal conflict with Masimo, a medical device manufacturer. The dispute centers around patent claims related to blood oxygen monitoring functionality integrated into Apple Watch smartwatches.

US International Trade Commission Dismisses Masimo’s Renewed Complaint

The United States International Trade Commission (ITC) recently declined to review a renewed complaint filed by Masimo. The complaint alleged that Apple infringed on Masimo’s patents concerning the pulse oximeter feature employed in the Apple Watch to measure blood oxygen levels.

Masimo initially brought forward these allegations as part of a broader, multiyear legal battle over intellectual property rights tied to wearable health technology. The refusal by the ITC to entertain Masimo’s renewed claims marks an important procedural win for Apple, which continues to defend its innovations in smartwatch health monitoring.

While this outcome favors Apple at this stage, the legal proceedings between the two companies remain ongoing, and no final resolution has been reached. The case highlights the intersection of advanced consumer technology and patented medical device technology, increasingly relevant as wearables incorporate more sophisticated health metrics.

This decision reflects the challenges in navigating intellectual property enforcement in emerging technologies that blend consumer electronics with health data monitoring. Industry observers anticipate further developments as both Apple and Masimo assert their respective rights over sensors and algorithms that track vital signs through wrist-worn devices.

Apple wins a key legal battle as the US International Trade Commission rejects Masimo’s renewed patent claim on Apple Watch’s blood oxygen feature.